ImmunoGen Stock Price, News & Analysis (NASDAQ:IMGN)

$11.68 +0.43 (+3.82 %)
(As of 02/22/2018 03:30 PM ET)
Previous Close$11.68
Today's Range$11.10 - $12.05
52-Week Range$2.43 - $12.05
Volume3.28 million shs
Average Volume3.39 million shs
Market Capitalization$1.55 billion
P/E Ratio-10.65
Dividend YieldN/A
Beta2.5

About ImmunoGen (NASDAQ:IMGN)

ImmunoGen logoImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:IMGN
CUSIP45253H10
Phone+1-781-8950600

Debt

Debt-to-Equity Ratio-0.03%
Current Ratio2.81%
Quick Ratio2.78%

Price-To-Earnings

Trailing P/E Ratio-10.6470588235294
Forward P/E Ratio-11.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$115.45 million
Price / Sales13.38
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($1.02)
Net Income$-96,010,000.00
Net Margins-83.03%
Return on EquityN/A
Return on Assets-38.44%

Miscellaneous

Employees385
Outstanding Shares132,250,000

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings results on Friday, February, 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $39.40 million for the quarter, compared to analyst estimates of $39.62 million. The company's revenue was up 185.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.39) earnings per share. View ImmunoGen's Earnings History.

Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2018?

9 brokerages have issued 1 year price objectives for ImmunoGen's stock. Their predictions range from $1.30 to $18.00. On average, they expect ImmunoGen's stock price to reach $9.47 in the next twelve months. View Analyst Ratings for ImmunoGen.

What are Wall Street analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:

  • 1. According to Zacks Investment Research, "ImmunoGen reported wider-than-expected loss in the fourth quarter of 2017. However, revenues increased massively Year-over-year. The company has made a significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. The company’s shares have outperformed the broader industry in a year’s time." (2/14/2018)
  • 2. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)
  • 3. Cowen Inc analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 13,376,094 shares, an increase of 10.7% from the January 12th total of 12,085,660 shares. Based on an average daily trading volume, of 3,192,151 shares, the short-interest ratio is presently 4.2 days. Approximately 10.3% of the company's stock are sold short.

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:

  • Stephen C. McCluski, Independent Chairman of the Board (Age 64)
  • Mark J. Enyedy, President, Chief Executive Officer, Director (Age 53)
  • David B. Johnston PhD, Chief Financial Officer, Executive Vice President (Age 61)
  • Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer (Age 59)
  • Craig Barrows, Executive Vice President, General Counsel, Secretary (Age 62)
  • Anna Berkenblit M.D., Vice President and Chief Medical Officer (Age 47)
  • Theresa G. Wingrove Ph.D., Vice President - Regulatory Affairs and Quality (Age 59)
  • Peter J. Williams, Vice President - Business Development (Age 62)
  • Stuart A. Arbuckle, Director (Age 51)
  • Mark A. Goldberg M.D., Independent Director (Age 62)

Who owns ImmunoGen stock?

ImmunoGen's stock is owned by many different of institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (8.37%), Redmile Group LLC (8.25%), BlackRock Inc. (6.40%), Franklin Resources Inc. (2.27%), Millennium Management LLC (2.22%) and Wells Fargo & Company MN (1.18%). Company insiders that own ImmunoGen stock include Craig Barrows, Daniel M Junius, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Who sold ImmunoGen stock? Who is selling ImmunoGen stock?

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Arrowstreet Capital Limited Partnership, Clearbridge Investments LLC, Deutsche Bank AG, Alambic Investment Management L.P., Pinnacle Associates Ltd., Fisher Asset Management LLC and Bank of New York Mellon Corp. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, Daniel M Junius and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

Who bought ImmunoGen stock? Who is buying ImmunoGen stock?

ImmunoGen's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Renaissance Technologies LLC, Teachers Advisors LLC, Sphera Funds Management LTD. and Macquarie Group Ltd.. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy ImmunoGen stock?

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of ImmunoGen stock can currently be purchased for approximately $11.68.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $1.55 billion and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. ImmunoGen employs 385 workers across the globe.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM, MA 02451-1477, United States. The biotechnology company can be reached via phone at +1-781-8950600 or via email at [email protected]


MarketBeat Community Rating for ImmunoGen (IMGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  283 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ImmunoGen (NASDAQ:IMGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.562.502.502.50
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.47$8.05$8.05$7.72
Price Target Upside: 6.30% upside64.96% upside64.96% upside37.55% upside

ImmunoGen (NASDAQ:IMGN) Consensus Price Target History

Price Target History for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ:IMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018HC WainwrightSet Price TargetBuy$18.00HighView Rating Details
2/8/2018Royal Bank of CanadaReiterated RatingOutperform -> Outperform$12.00MediumView Rating Details
11/3/2017Cantor FitzgeraldReiterated RatingHold$5.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$9.00N/AView Rating Details
8/30/2017Canaccord GenuityReiterated RatingBuy$8.00 -> $10.00MediumView Rating Details
8/29/2017CowenReiterated RatingHoldHighView Rating Details
8/29/2017Leerink SwannReiterated RatingOutperform -> BuyHighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
3/1/2017Morgan StanleyLower Price TargetUnderweight$2.50 -> $1.30N/AView Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$9.00 -> $5.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

ImmunoGen (NASDAQ:IMGN) Earnings History and Estimates Chart

Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ IMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2018Q4 2017($0.07)($0.10)$39.62 million$39.40 millionViewListenView Earnings Details
11/3/2017Q3 2017($0.19)($0.61)$26.09 million$8.50 millionViewN/AView Earnings Details
7/28/2017Q2 2017($0.17)($0.10)$30.59 million$39.02 millionViewN/AView Earnings Details
5/5/20173/31/2017($0.36)($0.20)$16.16 million$28.70 millionViewN/AView Earnings Details
2/17/2017Q2 2017($0.39)($0.39)$16.28 million$13.85 millionViewListenView Earnings Details
10/28/2016Q117($0.38)($0.51)$21.12 million$7.66 millionViewListenView Earnings Details
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$19.54 million$18.03 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.06)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.14)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.36)($0.31)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.23)($0.22)ViewN/AView Earnings Details
1/27/2011Q4 2010($0.22)($0.21)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.23)($0.19)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.24)($0.21)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.23)($0.21)ViewN/AView Earnings Details
1/28/2010Q4 2009($0.21)($0.23)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.20)($0.22)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.17)($0.21)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.10)($0.09)ViewN/AView Earnings Details
1/29/2009Q4 2008($0.15)($0.14)ViewN/AView Earnings Details
10/27/2008Q3 2008($0.21)($0.19)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.25)($0.27)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.21)($0.30)ViewN/AView Earnings Details
1/31/2008Q4 2007($0.11)($0.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ImmunoGen (NASDAQ:IMGN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.27)($0.23)($0.25)
Q2 20182($0.27)($0.27)($0.27)
Q3 20182($0.27)($0.27)($0.27)
Q4 20182($0.27)($0.27)($0.27)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for ImmunoGen (NASDAQ:IMGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ImmunoGen (NASDAQ IMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 70.99%
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ IMGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Daniel M JuniusDirectorSell25,000$11.68$292,000.00196,700View SEC Filing  
2/13/2018Daniel M JuniusDirectorSell46,667$10.01$467,136.67243,367View SEC Filing  
1/8/2018Richard J GregoryVPSell2,904$6.64$19,282.56273,577View SEC Filing  
9/15/2017Craig BarrowsVPSell37,050$6.81$252,310.5051,100View SEC Filing  
9/13/2017Craig BarrowsVPSell14,600$6.95$101,470.0051,100View SEC Filing  
12/15/2016Mark Alan GoldbergDirectorBuy20,000$1.80$36,000.0023,800View SEC Filing  
11/8/2016Mark J EnyedyCEOBuy25,000$1.83$45,750.00100,100View SEC Filing  
11/2/2016Craig BarrowsInsiderBuy10,000$1.71$17,100.0031,100View SEC Filing  
11/2/2016Richard J GregoryVPBuy16,600$1.78$29,548.0039,231View SEC Filing  
2/1/2016John LambertEVPSell3,889$8.22$31,967.58106,857View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.9022,631View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72169,615View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80106,857View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76170,618View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79106,857View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.0027,090View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.0010,000View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00159,812View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97106,857View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35154,115View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95106,857View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40154,115View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24106,857View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.0080,636View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.6037,500View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.2037,500View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.0080,636View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50106,857View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.0037,500View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75106,857View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.0073,336View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50106,857View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.0037,500View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.8173,336View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75106,857View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ImmunoGen (NASDAQ IMGN) News Headlines

Source:
DateHeadline
ImmunoGen Target of Unusually Large Options Trading (IMGN)ImmunoGen Target of Unusually Large Options Trading (IMGN)
www.americanbankingnews.com - February 22 at 7:44 AM
ImmunoGen, Inc. (IMGN) Director Sells $292,000.00 in StockImmunoGen, Inc. (IMGN) Director Sells $292,000.00 in Stock
www.americanbankingnews.com - February 21 at 9:14 AM
ImmunoGen (IMGN) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowImmunoGen (IMGN) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:01 PM
Can ImmunoGens Key Ovarian Cancer Candidate Drive Growth?Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
www.msn.com - February 14 at 3:22 PM
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
finance.yahoo.com - February 14 at 3:22 PM
ImmunoGen (IMGN) Rating Lowered to Hold at Zacks Investment ResearchImmunoGen (IMGN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 14 at 12:24 PM
Daniel M. Junius Sells 46,667 Shares of ImmunoGen, Inc. (IMGN) StockDaniel M. Junius Sells 46,667 Shares of ImmunoGen, Inc. (IMGN) Stock
www.americanbankingnews.com - February 14 at 12:16 PM
FY2018 Earnings Forecast for ImmunoGen, Inc. Issued By Cantor Fitzgerald (IMGN)FY2018 Earnings Forecast for ImmunoGen, Inc. Issued By Cantor Fitzgerald (IMGN)
www.americanbankingnews.com - February 14 at 11:18 AM
FY2018 Earnings Estimate for ImmunoGen, Inc. (IMGN) Issued By Leerink SwannFY2018 Earnings Estimate for ImmunoGen, Inc. (IMGN) Issued By Leerink Swann
www.americanbankingnews.com - February 14 at 11:18 AM
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow - NasdaqImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow - Nasdaq
www.nasdaq.com - February 13 at 3:20 PM
What's Behind ImmunoGen Inc.'s Brief Dip on Tuesday?What's Behind ImmunoGen Inc.'s Brief Dip on Tuesday?
finance.yahoo.com - February 13 at 3:20 PM
ImmunoGen, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.27) Per Share (IMGN)ImmunoGen, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.27) Per Share (IMGN)
www.americanbankingnews.com - February 13 at 7:44 AM
 Analysts Anticipate ImmunoGen, Inc. (IMGN) Will Announce Quarterly Sales of $14.88 Million Analysts Anticipate ImmunoGen, Inc. (IMGN) Will Announce Quarterly Sales of $14.88 Million
www.americanbankingnews.com - February 13 at 6:18 AM
Why ImmunoGen Jumped Higher TodayWhy ImmunoGen Jumped Higher Today
finance.yahoo.com - February 13 at 6:01 AM
ImmunoGen (IMGN) PT Set at $18.00 by HC WainwrightImmunoGen (IMGN) PT Set at $18.00 by HC Wainwright
www.americanbankingnews.com - February 12 at 6:34 PM
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues GrowImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow
finance.yahoo.com - February 12 at 3:21 PM
ImmunoGen (IMGN) Rating Increased to Strong-Buy at BidaskClubImmunoGen (IMGN) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - February 11 at 8:54 AM
Zacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) to Post -$0.26 EPSZacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) to Post -$0.26 EPS
www.americanbankingnews.com - February 11 at 5:14 AM
ImmunoGen, Inc. (IMGN) Short Interest UpdateImmunoGen, Inc. (IMGN) Short Interest Update
www.americanbankingnews.com - February 9 at 4:58 PM
Form 8-K IMMUNOGEN INC For: Feb 09 - StreetInsider.com - StreetInsider.comForm 8-K IMMUNOGEN INC For: Feb 09 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - February 9 at 3:27 PM
ImmunoGen (IMGN) Q4 Loss Wider, Revenues Rise Y/Y - NasdaqImmunoGen (IMGN) Q4 Loss Wider, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - February 9 at 3:27 PM
ImmunoGens (IMGN) CEO Mark Enyedy on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaImmunoGen's (IMGN) CEO Mark Enyedy on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 9 at 3:27 PM
Earnings Reaction History: ImmunoGen, Inc., 20.0% Follow-Through ... - NasdaqEarnings Reaction History: ImmunoGen, Inc., 20.0% Follow-Through ... - Nasdaq
www.nasdaq.com - February 9 at 3:27 PM
ImmunoGen Reports Pipeline Progress and 2017 Operating ResultsImmunoGen Reports Pipeline Progress and 2017 Operating Results
finance.yahoo.com - February 9 at 3:27 PM
Investors Are Undervaluing ImmunoGen Inc (NASDAQ:IMGN) By 44.20%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing ImmunoGen Inc (NASDAQ:IMGN) By 44.20%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - February 9 at 3:27 PM
ImmunoGen reports 4Q lossImmunoGen reports 4Q loss
finance.yahoo.com - February 9 at 3:27 PM
ImmunoGen (IMGN) Q4 Loss Wider, Revenues Rise Y/YImmunoGen (IMGN) Q4 Loss Wider, Revenues Rise Y/Y
finance.yahoo.com - February 9 at 3:27 PM
ImmunoGen (IMGN) Posts  Earnings Results, Misses Estimates By $0.01 EPSImmunoGen (IMGN) Posts Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - February 9 at 1:32 PM
Royal Bank of Canada Reaffirms "Outperform" Rating for ImmunoGen (IMGN)Royal Bank of Canada Reaffirms "Outperform" Rating for ImmunoGen (IMGN)
www.americanbankingnews.com - February 8 at 6:40 PM
Is a Surprise Coming for ImmunoGen (IMGN) This Earnings Season? - NasdaqIs a Surprise Coming for ImmunoGen (IMGN) This Earnings Season? - Nasdaq
www.nasdaq.com - February 8 at 3:20 PM
Is a Surprise Coming for ImmunoGen (IMGN) This Earnings Season?Is a Surprise Coming for ImmunoGen (IMGN) This Earnings Season?
finance.yahoo.com - February 8 at 3:20 PM
ImmunoGen Price Run-Up Driven By Potential Clinical Trial Data - Seeking AlphaImmunoGen Price Run-Up Driven By Potential Clinical Trial Data - Seeking Alpha
seekingalpha.com - February 6 at 3:21 PM
Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings? - NasdaqIs a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings? - Nasdaq
www.nasdaq.com - February 6 at 3:21 PM
Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?
finance.yahoo.com - February 5 at 3:20 PM
ImmunoGen, Inc. (IMGN) Given Average Rating of "Buy" by BrokeragesImmunoGen, Inc. (IMGN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 4 at 1:32 AM
ImmunoGen (IMGN) Soars: Stock Adds 10.3% in Session - NasdaqImmunoGen (IMGN) Soars: Stock Adds 10.3% in Session - Nasdaq
www.nasdaq.com - February 2 at 5:50 AM
ImmunoGen (IMGN) to Release Quarterly Earnings on FridayImmunoGen (IMGN) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - February 2 at 1:02 AM
Heres Whats Lifting ImmunoGen, Inc. Shares Today - Motley FoolHere's What's Lifting ImmunoGen, Inc. Shares Today - Motley Fool
www.fool.com - February 1 at 3:20 PM
HC Wainwright Starts Immunogen Inc. (IMGN) at Buy - StreetInsider.comHC Wainwright Starts Immunogen Inc. (IMGN) at Buy - StreetInsider.com
www.streetinsider.com - January 31 at 3:20 PM
Here's What's Lifting ImmunoGen, Inc. Shares TodayHere's What's Lifting ImmunoGen, Inc. Shares Today
finance.yahoo.com - January 31 at 3:20 PM
Heres Whats Lifting ImmunoGen, Inc. Shares TodayHere's What's Lifting ImmunoGen, Inc. Shares Today
www.fool.com - January 31 at 1:10 PM
$40.55 Million in Sales Expected for ImmunoGen, Inc. (IMGN) This Quarter$40.55 Million in Sales Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - January 27 at 6:12 AM
ImmunoGen Announces Conference Call to Discuss Its 2017 Operating ResultsImmunoGen Announces Conference Call to Discuss Its 2017 Operating Results
finance.yahoo.com - January 26 at 3:20 PM
Immunogen (IMGN) Names Stuart A. Arbuckle to Board - StreetInsider.comImmunogen (IMGN) Names Stuart A. Arbuckle to Board - StreetInsider.com
www.streetinsider.com - January 24 at 3:23 PM
ImmunoGen Appoints Stuart A. Arbuckle to Board of DirectorsImmunoGen Appoints Stuart A. Arbuckle to Board of Directors
finance.yahoo.com - January 24 at 8:50 AM
Stock Traders Buy Large Volume of Put Options on ImmunoGen (IMGN)Stock Traders Buy Large Volume of Put Options on ImmunoGen (IMGN)
www.americanbankingnews.com - January 19 at 3:10 AM
Why ImmunoGen, Inc. Jumped on Tuesday and Is Holding SteadyWhy ImmunoGen, Inc. Jumped on Tuesday and Is Holding Steady
finance.yahoo.com - January 11 at 3:28 PM
ImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from BrokeragesImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 10 at 1:44 AM
Insider Selling: ImmunoGen, Inc. (IMGN) VP Sells 2,904 Shares of StockInsider Selling: ImmunoGen, Inc. (IMGN) VP Sells 2,904 Shares of Stock
www.americanbankingnews.com - January 8 at 7:28 PM
-$0.07 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter-$0.07 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - January 8 at 3:30 AM

SEC Filings

ImmunoGen (NASDAQ:IMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ImmunoGen (NASDAQ:IMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ImmunoGen (NASDAQ IMGN) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.